In lung cancer, several inhibitors of PI3K/mTOR/Akt axis have been evaluated in clinical trials as single agent and/or combination therapies demonstrating relevant adverse events without a solid clinical benefit. This evidence concerns the gene PIK3CA and lung carcinoma.